SRS X-Knife (Linac-Based Stereotactic Radiosurgery) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stereotactic radiosurgery (SRS) is a non-invasive neurosurgical technique that delivers a high, precisely focused dose of ionising radiation to an intracranial target in a single session (or in a small number of fractions — hypofractionated SRS), while sparing surrounding brain tissue. Despite its name, no incision is made; the term "surgery" reflects the ablative precision achieved rather than a conventional operative approach.

The X-Knife refers specifically to Linac-based (linear accelerator-based) SRS — a method that uses a standard medical linear accelerator modified with a stereotactic frame or frameless image-guidance system, a micro-multileaf collimator (mMLC), and sophisticated planning software. Major platforms include BrainLab Novalis Tx, Varian Edge, and Elekta Versa HD. The high-energy X-ray beams converge at the target from multiple angles, so each individual beam deposits a tolerable dose while the cumulative dose at the isocenter is ablative.

Linac-based SRS competes with two other widely used platforms: Gamma Knife (Elekta), which uses 192 fixed cobalt-60 sources to deliver photon beams in a helmet-like configuration (frame-based only; generally preferred for small spherical targets and trigeminal neuralgia); and CyberKnife (Accuray), a robotic arm-mounted compact Linac with real-time tumour tracking, suited for fractionated SRS and spinal lesions. Linac-based SRS offers the advantage of treating larger, more irregular targets with mMLCs, performing hypofractionated SRS without changing platforms, and is available at the vast majority of radiotherapy centres globally, making it the most widely accessible SRS modality.

Treatment planning is performed with stereotactic-accuracy CT (1-mm slices) fused with MRI and, for AVMs, digital subtraction angiography (DSA). Dose is prescribed to the 50–90% isodose line enveloping the target volume. The Radiation Therapy Oncology Group (RTOG) dose limits guide maximum target diameter and dose selection to limit toxicity.

SRS X-Knife is indicated for a well-defined range of intracranial pathologies:

• Arteriovenous malformations (AVMs): SRS obliterates the AVM nidus by inducing progressive vascular sclerosis over 2–3 years. The Pollock-Flickinger AVM radiosurgery score (incorporating target volume, location, and prior haemorrhage) predicts outcome: Grade I–II lesions (small, superficial, no prior haemorrhage) achieve 70–85% obliteration. Limitations include the 2–3 year latency period before obliteration, during which bleeding risk persists.
• Acoustic neuroma (vestibular schwannoma): SRS is the treatment of choice for tumours <3 cm maximum dimension. Tumour control rates of 90–95% at 10 years are reported with marginal doses of 12–13 Gy. Hearing preservation (Gardner-Robertson Grade I/II) at 5 years is achieved in 40–60% of cases when treated with ≤13 Gy marginal dose — superior to microsurgical resection in similarly-sized tumours.
• Intracranial meningiomas: Skull-base Grade I meningiomas (cavernous sinus, petroclival, parasagittal) not amenable to safe total excision are ideal SRS targets. Local control rates of 90–95% at 5 years with marginal doses of 12–14 Gy are consistently reported. SRS complements surgical resection for Simpson Grade IV residual disease.
• Brain metastases: SRS to 1–4 brain metastases (and increasingly up to 10 lesions) provides equivalent overall survival to whole-brain radiotherapy (WBRT) with significantly better neurocognitive preservation. The EORTC/NCIC and QUARTZ (UK) trials established that SRS alone is appropriate for patients with limited (1–4) well-controlled metastases and good performance status (KPS ≥70).
• Trigeminal neuralgia: SRS delivers 70–90 Gy to the trigeminal nerve root entry zone. At the Barrow Neurological Institute, 75–80% of patients achieve initial pain freedom (BNI Class I–II), though retreatment rates of 20–30% at 5 years reflect the lower durability compared to microvascular decompression.
• Other indications: Glomus jugulare tumours, pituitary adenomas (residual after surgery), craniopharyngiomas, cerebral cavernous malformations (selected cases), and primary CNS lymphoma salvage.

Patient selection for Linac-based SRS requires a multidisciplinary neurosciences team (neurosurgeon, radiation oncologist, medical physicist, and neuroradiologist) and depends on multiple criteria:

• Lesion size: Conventionally <3–3.5 cm in maximum dimension for single-session SRS; larger lesions carry unacceptable risk of radiation oedema and necrosis with conventional doses. Hypofractionated SRS (3–5 fractions) extends eligibility to lesions up to 5–6 cm by allowing higher total biologically effective dose with improved normal tissue sparing.
• Lesion location: Superficial lesions in eloquent cortex may warrant hypofractionation or conventional surgery. Deep-seated, surgically inaccessible targets (cavernous sinus, brainstem, deep AVM nidus) are ideal for SRS.
• Performance status: Karnofsky Performance Status (KPS) ≥70 is generally required for elective SRS, particularly for brain metastases where systemic disease control is a co-determinant of outcome.
• Prior treatment: SRS can be used as primary treatment, adjuvant therapy post-surgery (e.g., post-resection cavity SRS for brain metastases), or salvage treatment after WBRT. Reirradiation SRS is increasingly employed for recurrent disease, with careful dose-volume constraints.
• Contraindications: Active connective tissue disease (radiosensitivity), genetic radiosensitivity syndromes (ataxia-telangiectasia), inability to remain still (may require general anaesthesia in children), and absence of a clearly defined stereotactic target. Pregnancy is an absolute contraindication.
• Frame vs frameless: Frame-based SRS (stereotactic head frame screwed to the skull) provides sub-millimetre accuracy and is preferred for small-target, high-dose single-fraction treatments. Frameless SRS (thermoplastic mask + cone-beam CT + online re-positioning — BrainLab/Varian Edge) offers patient comfort, suitability for fractionated regimens, and equivalent accuracy for most indications when image-guidance protocols are rigorously followed.

The SRS procedure involves several carefully coordinated stages:

• Immobilisation: Frame-based: a Leksell-type or BRW stereotactic frame is fixed to the skull under local anaesthesia. Frameless: a thermoplastic mask and bite block are custom-fabricated. The patient then undergoes stereotactic-quality CT (1-mm slices) and gadolinium-enhanced MRI for target delineation.
• Target delineation and planning: The neurosurgeon delineates the gross target volume (GTV); for AVMs, DSA images are co-registered with planning CT. The medical physicist and radiation oncologist create an isodose plan (typically BrainLab iPlan or Varian Eclipse) optimising target coverage (>95% of GTV receiving prescription dose) and conformality index, while keeping dose to optic apparatus, brainstem, and cochlea within tolerance (optic nerve ≤8 Gy; brainstem ≤12.5 Gy for single fraction).
• Linac platforms available: BrainLab Novalis Tx (ExacTrac image guidance), Varian Edge (optical surface monitoring + cone-beam CT), Elekta Versa HD (Agility 160-leaf MLC) — all capable of non-coplanar arc delivery (VMAT/RapidArc) and stereotactic precision.
• Comparison with Gamma Knife: Gamma Knife uses 192 cobalt-60 sources in a fixed geometry — inherently frame-based, sub-millimetre accuracy, mechanically robust, no MLC. Preferred for small spherical targets (<1.5 cm) and trigeminal neuralgia. Linac SRS is superior for irregular or large targets, hypofractionation, and institutions that cannot afford dedicated Gamma Knife units.
• Comparison with CyberKnife: CyberKnife (robotic arm + fiducial/X-sight spine tracking) enables real-time motion-adaptive SRS with no frame required. Particularly suited for spinal SRS and abdominal/thoracic SBRT, though intracranial outcomes are comparable to Linac SRS for most indications.
• Hypofractionated SRS (hSRS): Delivering 5–8 Gy per fraction over 3–5 fractions reduces the radiobiological dose to late-responding normal tissue, permitting higher total doses to larger targets. Particularly employed for large AVMs (>3 cm), large metastases post-resection, and optic apparatus-adjacent lesions.

SRS X-Knife offers compelling advantages over both open neurosurgery and conventional radiotherapy:

• Non-invasive with no incision: Eliminates surgical risks including haemorrhage, infection, CSF leak, and anaesthesia complications, making it suitable for patients who are medically unfit for craniotomy due to age, comorbidities, or anticoagulation.
• Outpatient or short-stay procedure: Single-session SRS is performed in 30–90 minutes of beam delivery (total session including setup: 2–4 hours). Patients return home the same day in most cases, minimising hospitalisation and its associated costs.
• Preserves normal brain architecture: The steep dose gradient outside the target volume means surrounding brain structures are exposed to a fraction of the ablative dose. This is particularly important for tumours adjacent to critical structures such as the optic apparatus, brainstem, and cochlea.
• Durable local control: For acoustic neuroma, meningioma, and small AVMs, SRS provides local control rates comparable to microsurgery, without the immediate morbidity of open surgery. Long-term (10-year) data support SRS as a primary treatment for these lesions.
• Neurocognitive preservation in brain metastases: Randomised trials (Chang et al., EORTC 22952) demonstrate significantly better memory, executive function, and quality of life compared to WBRT, by avoiding radiation to the uninvolved hippocampus and bilateral white matter tracts.
• Compatibility with systemic therapy: SRS can be delivered concurrently with most targeted therapies and immunotherapy agents, whereas WBRT often requires treatment breaks due to enhanced toxicity with some agents.

While SRS is generally well-tolerated, clinicians and patients should be aware of the following potential adverse effects:

• Radiation oedema: Vasogenic oedema surrounding the irradiated target may occur 3–12 months post-SRS, causing headache, nausea, focal neurological deficits, or seizures. Managed with dexamethasone in most cases; resolves spontaneously over weeks to months. Incidence is dose- and volume-dependent, occurring in ~10–15% of cases.
• Radiation necrosis: A more severe late reaction (6–24 months post-SRS) characterised by coagulative necrosis of irradiated tissue. Clinically indistinguishable from tumour recurrence on standard MRI; MR perfusion, PET-FDG, or MR spectroscopy assists differentiation. Symptomatic necrosis requiring surgery or bevacizumab treatment occurs in 2–5% of SRS cases.
• Hearing loss (acoustic neuroma): Serviceable hearing (Gardner-Robertson Grade I/II) is preserved in 40–60% of patients at 5 years. The cochlear dose (≤4 Gy to cochlear modiolus) is the main determinant; modern cochlea-sparing plans have improved hearing outcomes.
• Cranial nerve deficits: Trigeminal numbness or facial paresis can occur with high-dose SRS for acoustic neuroma (incidence <5% with modern marginal doses of 12–13 Gy) or cavernous sinus meningioma.
• AVM latency risk: Following SRS for AVM, the annual bleeding risk persists at its natural history rate (2–4%/year) for 2–3 years until obliteration occurs. Patients must be counselled that haemorrhage risk is not immediately eliminated.
• Secondary malignancy: Theoretical long-term risk; estimated incidence of radiation-induced malignancy <1 in 1,000 cases at 10 years. Risk is higher in younger patients, particularly children, and should be factored into decision-making.

Structured surveillance is essential after SRS to monitor response, detect complications, and guide further management:

• Immediate post-SRS (24–48 hours): Patients may experience headache, nausea, or fatigue from radiation reaction. A short course of dexamethasone (4 mg TDS) is often prescribed prophylactically, particularly for larger targets or when surrounding oedema was present pre-treatment.
• MRI surveillance: Gadolinium-enhanced MRI is performed at 3 months, 6 months, 12 months, then annually. For acoustic neuroma and meningioma, the expected initial response is tumour stabilisation followed by gradual reduction in size over 1–3 years. Transient "pseudo-progression" (apparent size increase due to central necrosis and oedema) can occur at 3–6 months and should not prompt premature re-treatment without additional imaging (perfusion MRI, FDG-PET).
• AVM monitoring: DSA is performed at 3 years post-SRS (or earlier if MRI/MRA suggests complete nidus obliteration) to confirm anatomical cure. MRI/MRA is used for interim surveillance. If obliteration is incomplete at 3 years, re-treatment or surgical resection may be considered.
• Audiological follow-up (acoustic neuroma): Pure tone audiometry and speech discrimination testing at 6 and 12 months, then annually, to track hearing trajectory. Hearing aid counselling is initiated proactively when decline is detected.
• Brain metastases follow-up: MRI every 2–3 months for the first year due to the systemic disease context. New metastases detected on surveillance scans can be treated with additional SRS sessions (salvage SRS) or, if numerous, WBRT.
• Trigeminal neuralgia follow-up: Pain scores (BNI scale) are recorded at 1, 3, and 6 months. Median time to pain relief is 4–6 weeks. Retreatment SRS can be offered for recurrence, with similar initial response rates but higher risk of trigeminal numbness.

The cost of Linac-based SRS reflects the sophisticated technology, planning resources, and specialist multidisciplinary team involved:

• Technology and machine costs: BrainLab, Varian Edge, and Elekta Versa HD linear accelerators with stereotactic upgrades cost USD 3–6 million to install and maintain. These capital costs are reflected in treatment fees.
• Treatment planning: Physics planning (2–4 hours by a specialist medical physicist), neurosurgical target delineation, and dosimetry review contribute substantially to the total cost. Planning for complex cases (AVM, multiple metastases) is more time-intensive.
• Country-specific costs: In India (AIIMS, Tata Memorial, Apollo, Fortis): INR 1,20,000–2,50,000 (USD 1,400–3,000). In the USA: USD 15,000–35,000 per SRS session. In the UK (private): GBP 8,000–15,000. In Germany: EUR 10,000–20,000. India offers a compelling cost advantage for international patients seeking high-quality SRS at accredited facilities.
• Number of isocenters and fractions: Single-target, single-session SRS is less expensive than multi-target SRS or hypofractionated regimens requiring additional machine time, physics planning iterations, and repeat imaging.
• Imaging costs: Pre-treatment MRI, CT myelogram, and DSA (for AVM) add to total costs. Surveillance imaging over 5–10 years also contributes to the long-term cost of care.
• Insurance coverage: SRS is covered by most major insurers in the USA, EU, and Australia when medically indicated (brain metastases, acoustic neuroma, meningioma). Cosmetic or experimental indications may not be covered; pre-authorisation is advisable.

Depending on the specific intracranial pathology, several alternatives to Linac-based SRS exist:

• Gamma Knife radiosurgery: Cobalt-60 based SRS system offering sub-millimetre accuracy and mechanical precision unaffected by gravity or gantry sag. Preferred for small spherical targets (<1.5 cm), trigeminal neuralgia, and complex multi-shot plans. Requires a dedicated facility and cobalt source replenishment. Outcomes for acoustic neuroma, meningioma, and brain metastases are equivalent to Linac SRS from randomised comparisons.
• CyberKnife (robotic SRS): Frameless, motion-adaptive SRS and SBRT platform with real-time tumour tracking. Equivalent intracranial outcomes; particular advantage for spinal SRS (SBRT) and intra-abdominal targets. Longer treatment sessions (30–60 minutes of beam-on time) due to serial arc delivery.
• Microsurgical resection: For large (>3 cm) or symptomatic intracranial tumours causing mass effect, open craniotomy and microsurgical resection provide immediate decompression and histological diagnosis. Risk profile includes bleeding, infection, CSF leak, and neurological deficit; appropriate for young patients with accessible lesions.
• Whole-brain radiotherapy (WBRT): Conventional radiotherapy to the entire brain (30 Gy in 10 fractions). Appropriate for patients with multiple (>10) brain metastases, leptomeningeal disease, or poor performance status not suitable for SRS. Associated with neurocognitive decline; memantine and hippocampal-avoidance WBRT (HA-WBRT) partially mitigate this.
• Observation (watch and wait): For small, incidentally discovered acoustic neuromas (<1.5 cm, no growth on serial MRI) or asymptomatic meningiomas in elderly patients, surveillance MRI every 6–12 months is appropriate and defers treatment until growth or symptoms occur.
• Proton beam therapy: Emerging alternative for selected intracranial targets (craniopharyngioma, paediatric medulloblastoma, chordoma) where the Bragg peak's dose distribution advantage reduces integral brain dose. Limited availability globally; significantly higher cost.